ArticleNature and science of sleep2025
SCUBE-1 Levels and Their Relationship with Endothelial Dysfunction in Obstructive Sleep Apnea Syndrome Patients.
Article in Nature and science of sleep, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- SCUBE-1 as a Biomarker Predictor for the Home Follow-Up and Hospitalization of SARS-CoV-2 Patients.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Obstructive sleep apnea syndrome (OSAS) increases the risk of vascular dysfunction by causing hypoxemia due to recurrent obstructions in the upper airway. This can put pressure on the vasculature and impair endothelial function. SCUBE-1 gains importance in OSAS as a biomarker that may reflect this dysfunction. We focused in this study on the association between levels of SCUBE-1 and endothelial dysfunction in patients suffering from OSAS. Methods: A study population of 75 individuals participated in the study. Participants were categorized as normal (n=18), mild OSAS (n=22), moderate OSAS (n=19) and severe OSAS (n=16) according to polysomnography findings. Evaluation parameters included SCUBE-1 levels, polysomnography measurements, flow-mediated dilatation (FMD), carotid intima-media thickness (CIMT), and comprehensive laboratory analyses. Results: SCUBE-1 levels were significantly higher in the severe OSAS group (15.8 ± 4.2 ng/mL, p<0.001). SCUBE-1 showed a moderate negative correlation with FMD (r = -0.248, p < 0.001) and a significant negative correlation with CIMT (r = -0.512, p < 0.001). ROC analysis demonstrated good diagnostic accuracy (AUC: 0.871, 95% CI: 0.797-0.945) for SCUBE-1 in identifying severe OSAS. Conclusion: OSAS severity correlates with the rise in SCUBE-1 levels, and this biomarker may serve as an important attribute in profiling endothelial dysfunction. SCUBE-1 can indeed be an effective biomarker to identify subtle changes in the vascular biology of OSAS patients and aid early interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.